Monograph Details
|
|
Musculoskeletal Disorders
> Bone disorders
|
|
BONIVA INJECTION |
| Manufacturer |
|
Roche and GlaxoSmithKline |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Bisphosphonate. |
| Generic Name |
|
Ibandronate (as monosodium monohydrate) 3mg/3mL; soln for IV inj. |
| Also |
|
• BONIVA
|
| Indications |
|
Treatment of postmenopausal osteoporosis. |
| Children |
Not recommended.
|
| Adults |
|
Must be given by healthcare professional. Give as IV bolus inj over 15–30 seconds. 3mg every 3 months; if dose is missed, give as soon as possible, then every 3 months from the date of last inj. |
| Contraindications |
|
Uncorrected hypocalcemia. Severe renal impairment (CrCl<30mL/min or serum creatinine >2.3mg/dL): not recommended. Tabs: Inability to stand or sit upright for at least 60 minutes. |
| Precautions |
|
Discontinue if esophageal irritation occurs. Treat disturbances of mineral metabolism first. Ensure adequate Vit. D and calcium intake. Inj: check renal function before each dose (see Contraindications). Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
May be antagonized by calcium, other multivalent cations (eg, magnesium, aluminum, iron, antacids); may interfere with absorption. Caution with aspirin, NSAIDs, other GI irritants. May interfere with bone-imaging agents. Concomitant nephrotoxic agents; monitor for renal toxicity. |
| Adverse Reactions |
|
GI upset, abdominal or musculoskeletal pain (may be severe), headache; dysphagia, esophagitis, esophageal or gastric ulcer, jaw osteonecrosis. Inj: inj site reactions, flu-like syndrome. |
| How Supplied |
Tabs 2.5mg—(available soon)
Tabs 150mg—3
Prefilled syringe (5mL)—1 (w. supplies) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
